ArticleDiscover oncology2026
A hepatic solitary fibrous tumor with giant cells and a review of the literature.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSolitary fibrous tumor (SFT) is a rare mesenchymal tumor usually occurring at the pleura. Primary hepatic SFT presents at the liver is extremely rare, and its nonspecific clinical-biological findings cause a considerable difficulty in differentiation from other hepatic tumors. CASE PRESENTATION: We reported a uncommon case of primary hepatic SFT, which was pathologically characterized by abundant multinucleated giant cells. A man in his 60 s was admitted for a long-standing right upper abdominal pain (more than several months). Magnetic resonance imaging (MRI) scan revealed a mass in the liver. A right hemihepatectomy was performed and the pathological diagnosis revealed a tumor consisting of spindle-shaped tumor cells arranged in various forms with the presence of sparsely scattered numerous giant cells. Based on immunohistochemical staining (STAT6 + /CD34 +) and the WHO risk stratification criteria (high-risk category, score 7), the tumor was diagnosed as primary hepatic malignant SFT with giant cells. The patient recovered after the surgery and was administrated to regular lenvatinib treatment without recurrence for a course of 25 months.
conclusionThe hepatic SFT with giant cells (SFT-gc) is an exceedingly rare variant of primary hepatic SFT. Because of its anatomic atypia, careful distinction should be made from other frequent hepatic tumors, and a high index of suspicion is essential for accurate histopathological diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.